Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Debra Ainge

- PMLiVE

Roche presents two-year data for spinal muscular atrophy treatment Evrysdi in children

The severe and progressive neuromuscular disease affects about one in every 10,000 babies

- PMLiVE

Eli Lilly and insitro collaborate to advance new treatments for metabolic diseases

Metabolic dysfunction-associated steatotic liver disease is estimated to affect 100 million people in the US

- PMLiVE

GSK’s RSV vaccine Arexvy shown to protect older adults across three seasons

The respiratory virus is estimated to impact 64 million people globally every year

- PMLiVE

Roche’s Itovebi combination granted FDA approval for advanced breast cancer

Approximately 310,720 women will be diagnosed with invasive breast cancer in the US this year

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives MHRA approval

About 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

PM Society Awards 2025 open for entries

The ceremony will be held at JW Marriott Grosvenor House in London on 14 March

- PMLiVE

Behavioural Data Offering from Medscape Global

See more about this new insights product, Medscape AffinityTM, which offers unparalleled insights into the online behaviour of 13M+ HCPs to help you make fully informed decisions around your brand and content...

Medscape Medical Affairs

- PMLiVE

Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults

Approximately 25,000 people in the UK are affected by the rare liver disease

- PMLiVE

PMLiVE’s T40 – results announced!

The list highlights the creative agencies that had the most impact on the UK healthcare sector in 2023

- PMLiVE

Merck’s Keytruda shows promise as perioperative head and neck cancer treatment

More than 58,450 new cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

Astellas and AviadoBio enter exclusive dementia gene therapy deal worth over $2bn

Frontotemporal dementia accounts for less than one in 30 cases of the neurodegenerative disorder

- PMLiVE

Merck and Mestag enter inflammatory disease partnership worth up to $1.9bn

The agreement will see Mestag use its platform designed to model the pathogenic role of fibroblasts

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links